Company / Cash & Equivalents
Q32 Bio Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$48.3M
FY2025
5-year range
$34.0M / $108.4M
FY2021-FY2025
Trend
-38.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $34M in FY2022 to $217M in FY2020.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of -26.0%.
Improved from $39M to $48M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +12.4%
- 5-Year CAGR
- -26.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -26.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 38.1% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.3M | -38.1% |
| FY2024 | $78.0M | +98.6% |
| FY2023 | $39.3M | +15.5% |
| FY2022 | $34.0M | -68.6% |
| FY2021 | $108.4M | -50.2% |
| FY2020 | $217.4M | +304.3% |
| FY2019 | $53.8M | +40.7% |
| FY2018 | $38.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026